|
Age (≥60/< 60, year)
|
0.922
|
0.463–1.837
|
0.818
|
–
|
–
|
–
|
|
Sex (Men/Women)
|
1.458
|
0.689–3.087
|
0.324
|
–
|
–
|
–
|
|
HBsAg (yes/no)
|
1.711
|
0.887–3.300
|
0.109
|
–
|
–
|
–
|
|
HCV antibody (yes/no)
|
6.405
|
1.491–27.524
|
0.013
|
9.142
|
2.028–41.225
|
0.004
|
|
AFP (≥20/< 20, ng/mL)
|
1.288
|
0.761–2.181
|
0.346
|
–
|
–
|
–
|
|
CEA (≥5/<5, ng/mL)
|
1.643
|
0.924–2.923
|
0.091
|
–
|
–
|
–
|
|
CA19–9 (≥37/<37, U/mL)
|
1.591
|
0.932–2.715
|
0.089
|
–
|
–
|
–
|
|
Liver cirrhosis, yes (%)
|
1.952
|
1.091–3.493
|
1.379
|
6.264
|
0.734–2.590
|
0.318
|
|
TB (≥17/< 17, μmol/L)
|
0.739
|
0.383–1.427
|
0.368
|
–
|
–
|
–
|
|
ALB (≥40/<40, g/mL)
|
0.814
|
0.476–1.391
|
0.451
|
–
|
–
|
–
|
|
ALT (≥35/<35, U/L)
|
1.459
|
0.869–2.452
|
0.153
|
–
|
–
|
–
|
|
γ-GT (≥40/<40, U/L)
|
1.811
|
0.933–3.515
|
0.079
|
–
|
–
|
–
|
|
PLT (≥10/< 10 103/μL)
|
1.353
|
0.683–2.682
|
0.386
|
–
|
–
|
–
|
|
Prothrombin time, median (range), s
|
1.014
|
0.547–1.880
|
0.964
|
–
|
–
|
–
|
|
Tumour size, cm
|
1.466
|
0.814–2.639
|
0.203
|
–
|
–
|
–
|
|
Tumour nodularities
|
1.017
|
0.785–1.318
|
0.898
|
–
|
–
|
–
|
|
Occlusion, min (< 20/≥20)
|
1.560
|
0.735–3.310
|
0.247
|
–
|
–
|
–
|
|
Macrovascular invasion (yes/no)
|
3.343
|
1.770–6.315
|
< 0.001
|
3.035
|
1.543–5.972
|
0.001
|
|
Microvascular invasion (yes/no)
|
1.359
|
0.725–2.546
|
0.338
|
–
|
–
|
–
|
|
Lymphoid metastasis (yes/no)
|
1.487
|
0.667–3.315
|
0.332
|
–
|
–
|
–
|
|
Extrahepatic metastasis (yes/no)
|
6.805
|
2.549–18.166
|
< 0.001
|
6.264
|
2.277–17.235
|
< 0.001
|
|
Preventive TACE (yes/no)
|
0.911
|
0.545–1.520
|
0.720
|
–
|
–
|
–
|
